ABP 710: Withdrawal of the marketing authorisation application
Amgen Europe B.V. withdrew its application for a marketing authorisation of ABP 710 for the treatment of inflammatory diseases.
The company withdrew the application on 27 May 2019.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').